Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
25%
Ph not_applicable
1
13%
Ph phase_4
4
50%

Phase Distribution

0

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution7 total trials
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
4(57.1%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(4)
Terminated(1)
Other(3)

Detailed Status

Completed4
unknown3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (28.6%)
Phase 44 (57.1%)
N/A1 (14.3%)

Trials by Status

unknown338%
withdrawn113%
completed450%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins

NCT04478721
completedphase_3

Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections

NCT03543436
completed

Temocillin in ESBL-Enterobacteriaceae Infections

NCT05413772
unknownphase_4

Temocillin Pharmacokinetics in Paediatrics

NCT02260102
unknownnot_applicable

Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients

NCT03557840
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04478721Phase 3

Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins

Completed
NCT03543436Phase 3

Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections

Completed
NCT05413772

Temocillin in ESBL-Enterobacteriaceae Infections

Completed
NCT02260102Phase 4

Temocillin Pharmacokinetics in Paediatrics

Unknown
NCT03557840Not Applicable

Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients

Unknown
NCT02959957Phase 4

Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections

Completed
NCT02681263Phase 4

Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae

Unknown
NCT01543347Phase 4

Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8